Abstract 184P
Background
The present study examines the possible impact related to the level of over-expression reported at +++ or ++ for HER2 on the magnitude of benefit achieved by adjuvant trastuzumab.
Methods
All patients with HER2-positive breast cancer, treated by trastuzumab and with available HER2 status by immuno-histochemistry (IHC) in the SIGNAL/PHARE prospective cohort were identified. Univariate and multivariate Cox proportional hazards models were performed to estimate associations between overall survival (OS) or disease free survival (DFS) and HER2 protein level of expression defined by +++ (IHC) or ++ (IHC) with a positive FISH. A propensity score and an inverse probability of treatment weighting (IPTW) approaches were performed to assess a possible variation of treatment effect according to HER2 status.
Results
The SIGNAL/PHARE prospective cohort included 5474 patients with HER2-positive early breast cancer treated by trastuzumab. HER2 +++ was observed in 4942 cases and HER2 ++ with amplification assessed by FISH in 532 tumors. At baseline, patients with HER2 +++ tumors had higher incidence of inflammatory cancers, larger tumors and higher rate of hormone receptor-negative tumors. No significant association between HER2 expression in IHC and overall survival was detected, in multivariate analyses adjusted for prognostic factors (p = 0.17; HR = 1.33[0.89-1.99]). No association between HER2 expression and overall survival appeared through the propensity score and IPTW analysis (p = 0.33; HR = 1.09[0.92-1.28]). The same methods failed to demonstrate an association between HER2 level of expression and DFS (p > 0.05 and p > 0.05 respectively).
Conclusions
The level of expression of HER2 determined by IHC ( ++ with positive-FISH versus +++) did not impact OS and DFS of patients in HER2-positive early breast cancer treated by trastuzumab.
Clinical trial identification
NCT00381901 – RECF1098
Legal entity responsible for the study
INCa: Institut National du cancer (France)
Funding
INCa
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract